What are the compound patents for pirtobrutinib?

Pirtobrutinib is a new type of Bruton's tyrosine kinase (BTK) inhibitor, and its compound patent is an important legal basis for protecting its innovation and market exclusivity. The drug was developed by Loxo Oncology (now a company of Eli Lilly and Company) and has applied for a number of patents surrounding its chemical structure, synthesis methods and uses. These patents cover the core active ingredient of pitobrutinib, ensuring its intellectual property protection during the drug development and production process.

Specifically, compound patents for pitobrutinib usually include patent rights for its molecular structure, preventing other companies from copying the same or very similar compounds. In addition, there are patents for synthesis processes. These patents describe in detail the manufacturing process of drugs from raw materials to finished products, ensuring technical barriers to drug production. There are also usage patents, which mainly cover the application of pitobrutinib in the treatment of various hematological tumors, such as chronic lymphocytic leukemia (CLL) and Waldenstrom's macroglobulinemia.

In addition to compound and synthesis method patents, pitobrutinib also involves patents related to dosage forms and combination medications. For example, a regimen that combines pitobrutinib with other anti-cancer drugs may also be subject to separate patent protection to extend its market life cycle and enhance efficacy. Such a multi-level patent layout gives the drug a strong competitive advantage in the process of research and development and commercial promotion.

In short, the compound patent of pitobrutinib covers its core molecular structure, synthesis method and therapeutic uses, forming a comprehensive intellectual property protection system. These patents not only protect Eli Lilly's innovative achievements, but also provide solid legal protection for future drug improvement and clinical application. With the continuous improvement and extension of the patent, pitobrutinib will continue to maintain its important position in the field of BTK inhibitors.

Reference materials:https://go.drugbank.com/drugs/DB17472